Efficacy and safety study to evaluate DX-2930 in preventing agioedema attacks in patients with Type I and Type II heriditary angioedema (HAE)

Registry ID
EUCTR2015-003943-20
Source registry
EUCTR
Status
Completed
Phase
PHASE3
Sponsor
Dyax Corp., an indirect, wholly-owned subsidiary of Shire plc.
Start date
2016-01-08
Completion date
2017-04-13
Last update
2026-08-16

Conditions

Summary

To evaluate the efficacy of DX-2930 in preventing HAE attacks

Locations

View on source registry